Tactile Systems Stock Price, News & Analysis

Tactile Medical (NASDAQ: TCMD), a medical technology company focused on therapies for chronic disorders, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 3:20 p.m. CST, followed by a presentation at the Jefferies Global Healthcare Conference in New York on June 4 at 2:35 p.m. EST.

Live audio webcasts of both presentations will be available on the company's investor relations website under the \"Events & Webcasts\" section, with replay options available after the conferences. Tactile Medical specializes in at-home therapies for conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.

Tactile Systems Technology (TCMD) has announced it will release its first quarter fiscal year 2025 financial results after market close on Monday, May 5, 2025. The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day.

Participants can join via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13752588. A live webcast will be available on the company's investor relations website, with a two-week replay available afterward.

Tactile Medical specializes in at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, focusing on improving patient self-care capabilities.

Tactile Medical (TCMD) has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, scheduled for March 17th-20th, 2025. The company's management will deliver a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time.

The presentation will be accessible via live audio webcast in the 'Events & Webcasts' section of Tactile Medical's investor relations website. Investors can access the webcast at investors.tactilemedical.com, with a replay option available after the conference.

Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease. The company focuses on enabling patients to better manage their conditions through home-based care, while collaborating with clinicians to expand clinical evidence and improve healthcare outcomes.

Tactile Medical (TCMD) reported strong Q4 2024 financial results with total revenue increasing 10% year-over-year to $85.6 million. The company achieved a gross margin of 75% and net income of $9.7 million in Q4 2024, compared to 72% and $8.2 million in Q4 2023, respectively.

For the full year 2024, total revenue grew 7% to $293.0 million, with gross margin improving to 74% from 71% in 2023. Operating cash flow reached $40.7 million, up from $35.9 million in 2023. The company ended 2024 with $94.4 million in cash, a significant increase from $61.0 million at the end of 2023.

Looking ahead, TCMD provided 2025 guidance projecting total revenue between $316-322 million (8-10% growth) and adjusted EBITDA of $35-37 million.

Tactile Systems Technology (TCMD) has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 18, 2025. The company will host a conference call with Q&A at 5:00 p.m. Eastern Time on the same day.

Participants can join via phone (877-407-3088 for domestic, 201-389-0927 for international) using access code 13751026. A live webcast will be available on the company's investor relations website, with a replay accessible for two weeks afterward.

Tactile Medical specializes in at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, focusing on helping patients manage their care at home.

Tactile Medical (NASDAQ: TCMD) has expanded the availability of its Nimbl™ pneumatic compression device to include treatment for lower extremity lymphedema across the United States. This expansion follows the initial October 2024 launch for upper extremity lymphedema treatment.

The Nimbl device represents significant technological advancement, being 68% lighter and 40% smaller than the company's current generation PCD, with 94% less hosing in its lower extremity garment. It is the only basic PCD featuring Bluetooth® connectivity, allowing patients to track treatments and symptoms through the free Kylee™ digital application.

This expansion targets a market of 16 million Americans with chronic swelling in lower extremities, offering them a more portable and user-friendly treatment option designed to improve patient adherence and care experience.

Tactile Medical (Nasdaq: TCMD) has appointed Laura King to its Board of Directors and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Laura King brings extensive experience from her 22-year career at General Electric Company (GE), where she served as President & CEO of GE Healthcare’s Global Interventional Business. Her leadership included roles as Chief Information Officer & Chief Financial Officer for GE's Consumer & ECM Motors segment.

Currently, Ms. King is the co-founder & CEO of BiaCure, Inc., and has previously co-founded Elucent Medical, positively impacting over 10,000 breast cancer patients. She also served as President & CEO of NeuWave Medical, which was acquired by Johnson & Johnson’s MedTech division. Bill Burke, Chairman of the Board of Tactile Medical, expressed enthusiasm for Ms. King's appointment, citing her experience in leading healthcare companies and developing innovative technologies as valuable assets for the company.

Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, aiming to improve patient care and reduce healthcare costs.

Tactile Medical (Nasdaq: TCMD) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace from December 3rd-5th. The company's management will engage in a fireside chat on December 3rd at 10:00 a.m. Central Time.

The event will be accessible via live audio webcast in the 'Events & Webcasts' section of Tactile Medical's investor relations website, with replay available post-conference. Tactile Medical specializes in at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.